David J Kuter, Jiri Mayer, Merlin Efraim, Lachezar H Bogdanov, Ross Ian Baker, Zane S Kaplan, Mamta Garg, Marek Trneny, Philip Y Choi, A J Gerard Jansen, Vickie McDonald, Robert J Bird, Jaromir Gumulec, Milan Kostal, Terry Gernsheimer, Waleed Ghanima, Ahmed Abd Almalik Daak, Nichola Cooper
Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study...
February 22, 2024: Blood Advances